Price
CHART BY
Frequently asked questions
What is Intellia Therapeutics's market capitalization?
The market capitalization of Intellia Therapeutics is $1.79B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Intellia Therapeutics?
Intellia Therapeutics's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.357. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Intellia Therapeutics's stock?
Currently, 19 analysts cover Intellia Therapeutics's stock, with a consensus target price of $23.75. Analyst ratings provide insights into the stock's expected performance.
What is Intellia Therapeutics's revenue over the trailing twelve months?
Over the trailing twelve months, Intellia Therapeutics reported a revenue of $59.51M.
What is the EBITDA for Intellia Therapeutics?
Intellia Therapeutics's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$408.23M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Intellia Therapeutics?
Intellia Therapeutics has a free cash flow of -$348.69M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Intellia Therapeutics have, and what sector and industry does it belong to?
Intellia Therapeutics employs approximately 377 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Intellia Therapeutics's shares?
The free float of Intellia Therapeutics is 133.92M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $1.79B
- EPS (TTM)
- -$3.357
- Free Float
- 133.92M
- Revenue (TTM)
- $59.51M
- EBITDA (TTM)
- -$408.23M
- Free Cashflow (TTM)
- -$348.69M
Pricing
- 1D span
- $12.69$13.47
- 52W span
- $7.95$28.24
Analyst Ratings
The price target is $23.75 and the stock is covered by 19 analysts.
Buy
10
Hold
6
Sell
3
Information
Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
- Employees
- 377
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- NTLA
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet